Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
2022 | Artificial intelligence-based immunoprofiling serves as a potentially predictive biomarker of nivolumab treatment for advanced hepatocellular carcinoma | Lee, Jan-Mou; Hung, Yi-Ping; Chou, Kai-Yuan; Lee, Cheng-Yun; Lin, Shian-Ren; Tsai, Ya-Han; Lai, Wan-Yu; YU-YUN SHAO ; CHIUN HSU ; CHIH-HUNG HSU ; Chao, Yee | Frontiers in medicine | 2 | 2 | |
2022 | Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma | YU-YUN SHAO ; HUNG-YANG KUO ; YUNG-MING JENG ; YAO-MING WU ; HSIU-PO WANG ; CHIUN HSU ; CHIH-HUNG HSU ; Hsu, Hey-Chi; ANN-LII CHENG ; ZHONG-ZHE LIN | BMC cancer | 3 | 3 | |
2009 | Association of clinical and dosimetric factors with postoperative pulmonary complications in esophageal cancer patients receiving intensity-modulated radiation therapy and concurrent chemotherapy followed by thoracic esophagectomy | Feng-Ming Hsu ; Lee Y.-C.; JANG-MING LEE ; CHIH-HUNG HSU ; CHIA-CHI LIN ; YU-CHIEH TSAI ; Wu J.-K.; CHIA-HSIEN CHENG | Annals of Surgical Oncology | 33 | 32 | |
2021 | Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance | Wang, Yulei; LI-CHUN LU ; Guan, Yinghui; MING-CHIH HO ; Lu, Shan; Spahn, Jessica; CHIH-HUNG HSU | Experimental hematology & oncology | 15 | 15 | |
2020 | Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study | Lee M.S.; Ryoo B.-Y.; CHIH-HUNG HSU ; Numata K.; Stein S.; Verret W.; Hack S.P.; Spahn J.; Liu B.; Abdullah H.; Wang Y.; He A.R.; Lee K.-H.; Bang Y.-J.; Bendell J.; Chao Y.; Chen J.-S.; Chung H.C.; Davis S.L.; Dev A.; Gane E.; George B.; He A.R.; Hochster H.; CHIUN HSU ; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Stein S.; Strickler J.; Tebbutt N. | The Lancet Oncology | 353 | 312 | |
2009 | The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma | ZHONG-ZHE LIN ; Hsu H.-C.; CHIH-HUNG HSU ; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; SUNG-HSIN KUO ; CHIUN HSU ; Hu F.-C.; YUNG-MING JENG ; Chung Y.; ANN-LII CHENG | Journal of Hepatology | 38 | 39 | |
2022 | AXL and MET in Hepatocellular Carcinoma: A Systematic Literature review | CHIH-HUNG HSU ; Huang Y.-H.; Lin S.-M.; CHIUN HSU | Liver Cancer | 6 | 6 | |
2022 | B Cells in Tumor Microenvironment Associated With The Clinical Benefit to Programmed Cell Death Protein-1 Blockade Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma | JHE-CYUAN GUO ; Hsu, Chia-Lang; YEN-LIN HUANG ; CHIA-CHI LIN ; TA-CHEN HUANG ; Wu, I-Chen; Lin, Chen-Yuan; Lien, Ming-Yu; HUNG-YANG KUO ; ANN-LII CHENG ; CHIH-HUNG HSU | Frontiers in oncology | 2 | 1 | |
2022 | Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety | YU-YUN SHAO ; Feng Y.-H.; Yen C.-J.; Yang T.-S.; YING-CHUN SHEN ; Chao Y.; Chen J.-S.; Su C.-Y.; Chen W.-J.; Hsiang H.-L.; CHIH-HUNG HSU | Journal of the Formosan Medical Association | 3 | 4 | |
2013 | Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study | CHIH-HUNG HSU ; Kang Y.K.; Yang T.-S.; CHIA-TUNG SHUN ; YU-YUN SHAO ; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; CHIUN HSU ; ANN-LII CHENG | Oncology (Switzerland) | 40 | 41 | |
2009 | Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway | Chen K.-F.; Yeh P.-Y.; CHIUN HSU ; CHIH-HUNG HSU ; YEN-SHEN LU ; Hsieh H.-P.; PEI-JER CHEN ; ANN-LII CHENG | Journal of Biological Chemistry | 89 | 84 | |
2013 | Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study | Johnson P.J.; Qin S.; Park J.-W.; Poon R.T.P.; Raoul J.-L.; Philip P.A.; CHIH-HUNG HSU ; Hu T.-H.; Heo J.; Xu J.; Lu L.; Chao Y.; Boucher E.; Han K.-H.; Paik S.-W.; Robles-Aviña J.; Kudo M.; Yan L.; Sobhonslidsuk A.; Komov D.; Decaens T.; Tak W.-Y.; Jeng L.-B.; Liu D.; Ezzeddine R.; Walters I.; ANN-LII CHENG | Journal of Clinical Oncology | 618 | 595 | |
2006 | Chemokine receptor expression profiles in nasopharyngeal carcinoma and their association with metastasis and radiotherapy | DA-LIANG OU ; Chen C.-L.; Lin S.B.; CHIH-HUNG HSU ; LIANG-IN LIN | Journal of Pathology | 61 | 52 | |
2002 | The chemopreventive compound curcumin is an efficient inhibitor of Epstein-Barr virus BZLF1 transcription in Raji DR-LUC cells | Hergenhahn M.; Soto U.; Weninger A.; Polack A.; CHIH-HUNG HSU ; ANN-LII CHENG ; Rösl F. | Molecular Carcinogenesis | 70 | 61 | |
2014 | Clinical activity of metronomic chemotherapy in liver cancers | YU-YUN SHAO ; ANN-LII CHENG ; CHIH-HUNG HSU | Metronomic Chemotherapy: Pharmacology and Clinical Applications | 0 | 0 | |
2014 | Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy | LI-CHUN LU ; YU-YUN SHAO ; Chan S.-Y.; CHIH-HUNG HSU ; ANN-LII CHENG | Anticancer Research | 12 | 10 | |
2007 | Clinical studies with curcumin | CHIH-HUNG HSU ; ANN-LII CHENG | Advances in Experimental Medicine and Biology | 359 | 305 | |
1993 | Cloning and expression of the gene encoding Acacia confusa trypsin inhibitor that is active without post-translational proteolysis | CHIH-HUNG HSU ; Ming-Chih L.; Ming-Tay L.; Jung-Yaw L. | Gene | 15 | 14 | |
2001 | Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma | CHIH-HUNG HSU ; Chen J.; Wu C.-Y.; ANN-LII CHENG ; YEONG-SHIAU PU | Anticancer Research | 27 | 24 | |
2002 | Combination of 13-cis retinoic acid and interferon-α in the treatment of recurrent or refractory peripheral T-cell lymphoma | Huang C.-L.; ZHONG-ZHE LIN ; Su I.-J.; Chao T.-Y.; HWEI-FANG TIEN ; Chang M.-C.; Huang M.-C.; Kao W.-Y.; JIH-LUH TANG ; KUN-HUEI YEH ; Wang C.-H.; CHIH-HUNG HSU ; Liu M.-Y.; ANN-LII CHENG | Leukemia and Lymphoma | 9 | 5 | |